Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial

Jørgen Hilden; Inga Lind; Hans Jørn Kolmos; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav Holger Helø; Per Hildebrandt; Gorm Boje Jensen; Jens Kastrup; Erik Kjøller; Henrik Nielsen; Lars Petersen; Christian M Jespersen; Christian Gluud; CLARICOR Trial Group

doi:10.1016/j.diagmicrobio.2009.11.011

Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial

Jørgen Hilden, Inga Lind, Hans Jørn Kolmos, Bodil Als-Nielsen, Morten Damgaard, Jørgen Fischer Hansen, Stig Hansen, Olav Holger Helø, Per Hildebrandt, Gorm Boje Jensen, Jens Kastrup, Erik Kjøller, Henrik Nielsen, Lars Petersen, Christian M Jespersen, Christian Gluud, CLARICOR Trial Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

8 Citationer (Scopus)

Abstract

Udgivelsesdato: 2010

Originalsprog	Engelsk
Tidsskrift	Diagnostic Microbiology and Infectious Disease
Vol/bind	66
Udgave nummer	4
Sider (fra-til)	385-92
Antal sider	8
ISSN	0732-8893
DOI	https://doi.org/10.1016/j.diagmicrobio.2009.11.011 https://doi.org/10.1016/j.diagmicrobio.2009.11.011
Status	Udgivet - 1 apr. 2010

Bibliografisk note

Adgang til dokumentet

Citationsformater

Hilden, J., Lind, I., Kolmos, H. J., Als-Nielsen, B., Damgaard, M., Hansen, J. F., Hansen, S., Helø, O. H., Hildebrandt, P., Jensen, G. B., Kastrup, J., Kjøller, E., Nielsen, H., Petersen, L., Jespersen, C. M., Gluud, C., & CLARICOR Trial Group (2010). Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial. Diagnostic Microbiology and Infectious Disease, 66(4), 385-92. https://doi.org/10.1016/j.diagmicrobio.2009.11.011, https://doi.org/10.1016/j.diagmicrobio.2009.11.011

Hilden, J, Lind, I, Kolmos, HJ, Als-Nielsen, B, Damgaard, M, Hansen, JF, Hansen, S, Helø, OH, Hildebrandt, P, Jensen, GB, Kastrup, J, Kjøller, E, Nielsen, H, Petersen, L, Jespersen, CM, Gluud, C & CLARICOR Trial Group 2010, 'Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial', Diagnostic Microbiology and Infectious Disease, bind 66, nr. 4, s. 385-92. https://doi.org/10.1016/j.diagmicrobio.2009.11.011, https://doi.org/10.1016/j.diagmicrobio.2009.11.011

@article{074645808b4e11df928f000ea68e967b,

title = "Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial",

abstract = "The association observed between coronary heart disease (CHD) and Chlamydia (Chlamydophila) pneumoniae antibodies prompted, during the 1990s, several primary and secondary prevention trials with various antibiotics. In our CLARICOR trial, a randomized placebo-controlled trial in 4372 patients with stable CHD, a brief clarithromycin regimen was followed, unexpectedly, by increased long-term mortality. We now compare C. pneumoniae antibody levels at entry with population levels, with the patients' individual histories, and with their subsequent outcomes. IgG antibody levels were somewhat raised, but elevated IgA and IgG titers were unrelated to entry data (including prior acute myocardial infarction), except for an association with smoking and with not using statins. Hazards of mortality and of other outcomes tended to slightly increase with IgA and decrease with IgG titers, but the unfavorable clarithromycin effect was unrelated to antibody levels and remains unexplained. Smoking-related lung disease probably underlies the link between heart disease and increased IgG titers.",

author = "J{\o}rgen Hilden and Inga Lind and Kolmos, {Hans J{\o}rn} and Bodil Als-Nielsen and Morten Damgaard and Hansen, {J{\o}rgen Fischer} and Stig Hansen and Hel{\o}, {Olav Holger} and Per Hildebrandt and Jensen, {Gorm Boje} and Jens Kastrup and Erik Kj{\o}ller and Henrik Nielsen and Lars Petersen and Jespersen, {Christian M} and Christian Gluud and Nielsen, {Henrik Anker}",

note = "Keywords: Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Coronary Disease; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Placebos; Prognosis; Risk Factors",

year = "2010",

month = apr,

day = "1",

doi = "10.1016/j.diagmicrobio.2009.11.011",

language = "English",

volume = "66",

pages = "385--92",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial

AU - Hilden, Jørgen

AU - Lind, Inga

AU - Kolmos, Hans Jørn

AU - Als-Nielsen, Bodil

AU - Damgaard, Morten

AU - Hansen, Jørgen Fischer

AU - Hansen, Stig

AU - Helø, Olav Holger

AU - Hildebrandt, Per

AU - Jensen, Gorm Boje

AU - Kastrup, Jens

AU - Kjøller, Erik

AU - Nielsen, Henrik

AU - Petersen, Lars

AU - Jespersen, Christian M

AU - Gluud, Christian

AU - CLARICOR Trial Group

N1 - Keywords: Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Coronary Disease; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Placebos; Prognosis; Risk Factors

PY - 2010/4/1

Y1 - 2010/4/1

N2 - The association observed between coronary heart disease (CHD) and Chlamydia (Chlamydophila) pneumoniae antibodies prompted, during the 1990s, several primary and secondary prevention trials with various antibiotics. In our CLARICOR trial, a randomized placebo-controlled trial in 4372 patients with stable CHD, a brief clarithromycin regimen was followed, unexpectedly, by increased long-term mortality. We now compare C. pneumoniae antibody levels at entry with population levels, with the patients' individual histories, and with their subsequent outcomes. IgG antibody levels were somewhat raised, but elevated IgA and IgG titers were unrelated to entry data (including prior acute myocardial infarction), except for an association with smoking and with not using statins. Hazards of mortality and of other outcomes tended to slightly increase with IgA and decrease with IgG titers, but the unfavorable clarithromycin effect was unrelated to antibody levels and remains unexplained. Smoking-related lung disease probably underlies the link between heart disease and increased IgG titers.

AB - The association observed between coronary heart disease (CHD) and Chlamydia (Chlamydophila) pneumoniae antibodies prompted, during the 1990s, several primary and secondary prevention trials with various antibiotics. In our CLARICOR trial, a randomized placebo-controlled trial in 4372 patients with stable CHD, a brief clarithromycin regimen was followed, unexpectedly, by increased long-term mortality. We now compare C. pneumoniae antibody levels at entry with population levels, with the patients' individual histories, and with their subsequent outcomes. IgG antibody levels were somewhat raised, but elevated IgA and IgG titers were unrelated to entry data (including prior acute myocardial infarction), except for an association with smoking and with not using statins. Hazards of mortality and of other outcomes tended to slightly increase with IgA and decrease with IgG titers, but the unfavorable clarithromycin effect was unrelated to antibody levels and remains unexplained. Smoking-related lung disease probably underlies the link between heart disease and increased IgG titers.

U2 - 10.1016/j.diagmicrobio.2009.11.011

DO - 10.1016/j.diagmicrobio.2009.11.011

M3 - Journal article

C2 - 20226329

SN - 0732-8893

VL - 66

SP - 385

EP - 392

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

IS - 4

ER -